Sep 14, 2026 09:40AM
Sep 11, 2026 07:05AM
Aug 5, 2026 04:05PM
Jun 25, 2026 06:17AM
Jun 22, 2026 08:01AM
Jun 22, 2026 08:00AM
May 21, 2026 05:00PM Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 19, 2026 08:00AM
May 19, 2026 08:00AM
May 5, 2026 04:05PM
Feb 10, 2026 04:05PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM
Feb 2, 2026 08:00AM Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Mar 26, 2025 01:08PM
Mar 26, 2025 01:07PM
Feb 11, 2025 04:05PM
Jan 24, 2025 02:31PM
Jan 24, 2025 02:30PM
Jan 13, 2025 12:50PM
Jan 12, 2025 04:00PM Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
Jan 9, 2025 09:00AM
Nov 27, 2024 07:08AM
Nov 26, 2024 04:05PM
Oct 29, 2024 04:05PM
Oct 16, 2024 06:54AM
Oct 16, 2024 06:03AM
Sep 16, 2024 02:01PM Citi Reiterates Buy Rating on Exelixis (EXEL)
Sep 16, 2024 08:45AM
Sep 16, 2024 08:45AM
Aug 6, 2024 04:05PM
Aug 6, 2024 08:30AM
Aug 6, 2024 08:30AM
Feb 14, 2024 08:30AM
Nov 2, 2021 04:05PM Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Sep 20, 2021 11:30AM
Sep 20, 2021 11:30AM
Sep 17, 2021 04:24PM
Sep 17, 2021 04:23PM
Aug 5, 2021 04:05PM
Aug 5, 2021 08:01AM
Aug 5, 2021 08:00AM Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen
Apr 29, 2021 06:59AM
Jan 22, 2021 01:10PM
Jan 10, 2021 04:00PM
Nov 5, 2020 04:05PM
Nov 5, 2020 06:59AM
Oct 19, 2020 07:00AM
Oct 19, 2020 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma
Dec 5, 2018 01:33AM

15,828 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All